Related Experiment Videos

The development of coronary insufficiency during prolonged treatment of essential hypertension

U V Kalnins1, I J Skarda, D J Liepinja

  • 1Latvian Research Institute of Cardiology, Riga, USSR.

Cor Et Vasa
|January 1, 1990
PubMed

Insights

Essential hypertension treatment can lead to coronary insufficiency, including angina and myocardial infarction. Even with normalized blood pressure and reduced heart muscle thickening, coronary issues may still arise.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Medicine

Background:

  • Essential hypertension is a major risk factor for cardiovascular disease.
  • Left ventricular myocardial hypertrophy is a common complication of hypertension.
  • Long-term antihypertensive therapy aims to prevent cardiovascular events.

Purpose of the Study:

  • To analyze the occurrence of coronary insufficiency signs during prolonged combined treatment of essential hypertension.
  • To investigate the relationship between left ventricular myocardial hypertrophy and coronary events.
  • To assess the impact of antihypertensive therapy on coronary insufficiency in hypertensive patients.

Main Methods:

  • Analysis of 42 patients with essential hypertension and left ventricular myocardial hypertrophy.
  • Four-year follow-up of antihypertensive therapy.
  • Assessment of angina pectoris, myocardial infarction, and ischemic ECG changes (bicycle ergometry, transesophageal atrial pacing).

Main Results:

  • 17% developed angina pectoris, 7% had myocardial infarction, and 36% showed ischemic ECG changes.
  • In patients with insufficient blood pressure control and severe hypertrophy, coronary insufficiency occurred in 53%.
  • Stable pressure normalization and hypertrophy regression did not prevent coronary insufficiency.

Conclusions:

  • Prolonged antihypertensive treatment in patients with myocardial hypertrophy carries a risk of coronary insufficiency.
  • Inadequate blood pressure control exacerbates this risk.
  • Coronary insufficiency can develop even with normalized blood pressure and hypertrophy regression, including during beta-blocker therapy.

Related Concept Videos